Adenine inhibited the de novo synthesis of purines in both normal and gouty man as shown by inhibition of the incorporation of glycine-15 N into urinary uric acid without altering the incorporation of glycine-15 N into urinary creatinine. The diminished purine synthesis did not result in a diminution in the 24 hr excretion of uric acid. This observation was explainable in part by the prompt conversion of adenine to uric acid. In addition to this direct conversion, adenine-8-13 C provided a slow and prolonged contribution to urinary uric acid.
INTRODUCTION
A suppression of purine synthesis de novo can be induced by the preferential utilization of exogenously supplied preformed purines in a variety of biological systems. This was observed by Abrams in rabbit bone marrow slices (1) , by Gots in bacterial mutants (2) , by Nierlich and Magasanik in mouse fibroblasts grown in tissue culture (3) , and by Henderson in ascites tumor cells (4) . In addition, the administration of the purine precursor 4-amino-5-imidazole carboxamide (AIC) to the human subject has been noted to suppress incorporation of glycine-15N into urinary uric acid (5) .
The precise mechanism of the suppression of purine synthesis is not well understood. Caskey, Ashton, and Wyngaarden demonstrated that adenine-containing nucleotides as well as those containing guanine or hypoxanthine exert an inhibitory action on the enzyme responsible for the rate-controlling step of purine synthesis (Fig. 1 ). This enzyme, phosphoribosylpyrophosphate glutamine amidotransferase, is responsible for the formation of phosphoribosylamine from glutamine and phosphoribosylpyrophosphate (6) . The finding that adenine-14C administered in trace quantities was converted to uric acid at a very slow rate (7) suggested the possibility that larger doses of adenine might be used to inhibit, in a physiological manner, the excessive purine synthesis found in some patients with gout without itself being degraded immediately to uric acid.
In the present study we have observed the effect of the administration of adenine on purine synthesis de novo as measured by the incorporation of glycine-'5N into urinary uric acid in normal and gouty subjects. Simultaneous determination of the dynamics of the urate pool by means of uric acid-2-'4C intravenously "administered has permitted the appropriate correction for the extrarenal disposition of uric acid in the various subjects (8). Adenine-8-'3C was used in order to The Journal of Clinical Investigation Volume 47 1968 assess the extent to which exogenous adenine was converted to urinary uric acid.
METHODS
Adenine-8-3C -HCI -1/2 H20, containing 9.89 atom % excess 13C, was synthesized by a modification of the procedure of Clark and Kalckar (9) (10) (11) . '3C02 was liberated from barium carbonate-s'3C (71.3 mmole; 55.7 atom % excess "C, Eastman Kodak, Rochester, N. Y.) by the action of orthophosphoric acid, entrained in carbon dioxide-free nitrogen, and trapped in sodium hydroxide. The solution was cooled to 0'C, titrated to pH 8.5 with sulfuric acid, and the 'C-labeled sodium bicarbonate was reduced to sodium formate by hydrogen (24 hr at 80'C and 3700 psi in the presence of 10 g of pallidized charcoal [1 g of Pd]) (12) . Formic acid-`C was isolated by steam distillation, the distillate titrated to pH 8.4 with sodium hydroxide, and finally evaporated to dryness to yield sodium formate-"8C.
N(4,6-diamino-5-pyrimidinyl)-formamide-"C was prepared from 4,5,6-triaminopyrimidine (Sigma Chemical Co., St. Louis, Mo.) (11) and converted to adenine-8-"C by heating at 210°C in diethanolamine under nitrogen for 90 min (10) . After cooling the reacting mixture on ice we neutralized the diethanolamine by the addition of an equivalent quantity of concentrated hydrochloric acid and isolated adenine as the picrate. Adenine picrate was converted to adenine hydrochloride by treatment with a saturated solution of dry hydrogen chloride in anhydrous acetone. The last traces of picric acid were removed by stirring an aqueous solution of the adenine hydrochloride with Dowex -1 X 8 (200400 mesh, Cl-form). The ion exchange resin was removed by filtration, adenine hydrochloride hemihydrate was crystallized from the filtrate, and recrystallized three times from hot water. The overall yield from barium carbonate was 52%.
The molar absorbency index of the synthesized adenine hydrochloride hemihydrate -8-" C (C5H5N5 -HCl /2 H20) at pH 2e= = 13,345 and the elemental analysis was as follows: calculated: C, 33.47; H, 3.90; N, 38.6; Cl, 19.57 found: C, 33.25; H, 3.86; N, 38.9; Cl, 19.41 (Correcting for "3C)
Glycine containing 97.96 atom %o excess "N was synthesized from potassium phthalimide-"N (Iso-met Corporation) (13, 14) . Uric acid-2-"'C was synthesized as previously described (15) :id pounds and throughout the period of study. All drugs with the exception of maintenance doses of colchicine were discontinued before starting the equilibration period. A fluid intake of at least 3 liters/day was maintained during the 2-day period immediately after adenine administration in order to minimize the hazard of renal deposition of the 2,8-dioxyadenine formed from adenine by xanthine oxidase action. Such a deposition has been shown to constitute the principal toxic effect of adenine administration in the rat (16) . The largest dose of orally administered adenine that could be given to the rat without causing renal deposition of 2,8-dioxyadenine or other toxic manifestations was found to be 25-50 mg/kg body weight. An additional margin of safety in translating these studies to the human subject is the fact that the specific activity of xanthine oxidase in human liver is only one-fiftieth the activity of rat liver (17, 18). Adenine-8-C HCl l/2 H20, 11.25 mg/kg body weight, along with carrier adenine, 3.6 mg/kg body weight, (Sigma Chemical Co.), was dissolved in a minimum volume of water and administered in orange juice with breakfast. Glycine-N was diluted with carrier glycine (Fisher Scientific Co., Pittsburgh, Pa.) to 60.0 atom %o excess in order that data could be directly compared with previous control studies performed on two subjects, G. S. and J. S., (8) and 100 mg/kg body weight was given in breakfast milk immediately after the intravenous administration of 8 mg of lithium urate-2-"C. A period of at least 6 months elapsed betwen control studies with glycine-m'N and urate-2-"C and studies with glycine-'lN, urate-2-w"C, and adenine-'3C. Serum urate was determined daily (19) . All urine was collected at room temperature with 3 ml of toluene as preservative, analyzed for uric acid (19) and creatinine content (20) , and then stored at -50 C until isolation procedures could be carried out. Uric acid was isolated from urine as previously described (21) . Creatinine was isolated from urine as the picrate and recrystallized as creatinine zinc chloride (22) . The content of '1C and '5N in uric acid and the abundance of I5N in creatinine were determined in a consolidated-Nier mass spectrometer after appropriate digestion of samples (23) .
Residual '5N found in uric acid during the 2 days before adenine administration was taken as the natural abundance value for the second study. The "C content of uric acid was determined by plating uric acid on planchets and by counting at 30% efficiency in a shielded end-window gasflow counter (Nuclear-Chicago Corp., Des Plaines, Ill.) with coincidence circuitry to give a background of less than 2 cpm. Counts of all samples were corrected to a standard thickness represented by 50 mg of uric acid.
Selected specimens of uric acid were degraded to alloxantin to separate the nitrogen atoms of positions 7 and 9 from those of 1 and 3 (24, 25) .
RESULTS
Adenine administration diminished the incorporation of glycine-15N into urinary uric acid in both normal and gouty subjects (Figs. 2 and 3) . The maximum enrichment of uric acid with 15N was reached in control subjects (Fig. 2) by the 3rd-4th day at values of 0.1 and 0.13 atom% excess. Adenine administration resulted in a substantially lower enrichment of 15N in each sample of uric acid. In the control studies of three gouty patients the maximum enrichment was found on the 1st or 2nd day, with maximum values of 0.3-0.8 atom% excess, about three to six times the values found in normal subjects. Adenine administration not only diminished glycine incorporation into urinary uric acid but also changed the time course of 15N enrichment. The early peak of 15N incorporation characteristic of gouty subjects with excessive uric acid synthesis was abolished and the time of appearance of maximum incorporation was delayed. Although adenine administration to gouty patients diminished the atom per cent excess 15N found in uric acid to values approaching those found in the control studies of normal subjects, they nonetheless remained substantially greater than the values found when the same control subjects were given adenine. This effect of adenine was also reflected in the total recovery of 15N in urinary uric acid shown in Table I .
The magnitude of the inhibition of glycine-15N incorporation into urinary uric acid in response to adenine varied greatly among the various subjects. In the normal subjects the total recovery of 15N in urinary uric acid was reduced to 26 and 52%o of control values, respectively, while in the gout patients it was reduced to 31-55% of control values. The 7 day total recovery in the urine of the intravenously administered uric acid-2-14C was used to correct for the extrarenal disposition of uric acid. The urate pool size and turnover rate (Table II) were not altered significantly by the administration of adenine. The close agreement of the per cent of urate turnover excreted each day (Table II) and the per cent of urate-2-"4C recovered in the urine (Table I) provides independent confirmation of the validity of these determinations. Glycine initially contributes primarily to the tions. Adenine administration diminished the spe-7 nitrogen position of the purine ring and only cific contribution of 15N to position 7 and 9 to secondarily to the remaining nitrogens through a a greater extent than the contribution to positions labeling of the body ammonia and glutamine pools. 1 and 3 of the purine ring in three of four patients Suppression of purine synthesis during the period Table III ). The incorporation of glycine-15N into of maximal labeling of the body's glycine pool urinary creatinine was not affected significantly should, therefore, suppress principally the primary by adenine administration (Table IV) . contribution of glycine to position 7 of uric acid.
The suppression of glycine-'5N incorporation The secondary contribution to the remaining 1, 3, into urinary uric acid was not reflected in a net and 9 positions from the glutamine and ammonia decrease in the serum urate concentration or in pools would be expected to be diminished to a the 24 hr excretion of uric acid (Fig. 4) . In fact, lesser extent since the glutamine and ammonia urinary uric acid excretion was substantially pools show a more prolonged pattern of labeling greater during the day of adenine administration with 15N (26, 27) . Degradation of uric acid than during the control study in four of the five allowed specific determination of 15N enrichment subjects. at the 1, 3 and, by difference, at the 7, 9 posi-A possible explanation for the transient increase C, control study; Ad, study with adenine. Atom per cent excess 15N in position 1, 3 was determined in alloxantin derived from uric acid, while that in position 7, 9 was calculated by difference. in urinary uric acid excretion was found in the prompt conversion of adenine-8-13C to urinary uric acid shown in Fig. 5 . The magnitude of the 18C enrichment of urinary uric acid was similar for both normal and gouty subjects. As a result, the total recovery of 13C in urinary uric acid was largely determined by the daily uric acid production (Table I ). The atom per cent excess 13C in urinary uric acid reached a maximum on the 1st or 2nd day in each patient and the subsequent decline in isotope abundance between the 3rd and 7th day followed first-order kinetics, as shown by the linear relationship when the values for isotope abundance were plotted on a logarithmic scale with time (Fig. 6) constitute a difference in quantitative aspects of the regulatory mechanism rather than a qualitative loss of the ability to respond to these agents. Support for this view has come from studies in which excessive purine synthesis has been associated with a complete absence of the enzyme hypoxanthine phosphoribosyltransferase (PRTase) (E. C. 2.4.2.8) in children with a familial neurological disease (28) and with a partial deficiency of the same enzyme in certain patients with gout who produce excessive quantities of uric acid (29 (29) . This enzyme deficit interferes with the reutilization of hypoxanthine and guanine for nucleotide formation (Fig.  1 ) and may be correlated with the earlier appearance of maximal 13C labeling of urinary uric acid in this patient and an earlier decline in isotope abundance than was observed in the other patients (Fig. 5) . The relative contribution of 15N from the glutamine pool was significantly greater in this patient and in the other gout patients, than in normal subjects, as shown by the lower ratio of isotope abundance in positions 7 and 9 of uric acid as compared to 1 and 3 during control studies and after adenine administration (27) . This type of 15N distribution has been taken as indirect evidence of a postulated deficiency of glutaminase (30) . However, no defect in glutaminase has yet been found (31) . The presence of this lower ratio, in a patient who has a deficiency of PRTase, suggests that the abnormal distribution of 15N is related to the presence of excessive uric acid production in some less specific manner that is not immediately apparent.
Suppression of Purine Synthesis by Adenine
Despite the decrease in glycine-15N incorporation into urinary uric acid the total amount of uric acid appearing in the 24 hr urine was not decreased by adenine administration in the present study. On the contrary, a transient increase in urinary uric acid above values found in control subjects was observed during the 2 days after adenine administration in four of the five subjects studied, and this was greater than could be accounted for by the fraction of administered adenine which appeared in urinary uric acid. Possible explanations of this observation include a mild uricosuric effect induced by adenine or its metabolites, or an enhanced degradation of tissue nucleotides induced by adenine. An increase in urinary uric acid was also found during the 2 days after AIC administration and was attributed to a direct conversion of AIC to uric acid (5) .
The rapid conversion of adenine-8-13C to uric acid-13C found in this study is different from the slow conversion of adenine-14C to urinary uric acid previously reported (7) . This discrepancy is undoubtedly related to the fact that a trace dose of adenine-8-14C was used in the earlier study whereas a loading dose of adenine-8-13C was used in the current study. Evidently under the conditions we used, a substantial portion of the adenine was degraded by a fairly direct pathway to uric acid to account for the prompt appearance of 13C in urinary uric acid as well as the increased uric acid excreted on the day adenine was administered. As shown in Fig. 1 , there is no adenine deaminase to catalyze the direct deamination of free adenine to hypoxanthine in mammalian tissue. The degradation to uric acid must, therefore, have occurred after conversion of the adenine to its nucleotide by adenine phosphoribosyltransferase (A-PRTase) or to its nucleoside by purine nucleoside phosphorylase. Although patient R. J. has only 1% of normal PRTase activity, he has a very active A-PRTase and so would be expected to incorporate adenine into nucleotides very effectively.
In addition, the incorporation of a portion of adenine-8-13C into tissue nucleic acids and other tissue nucleotides is a possible explanation for the continued slow contribution of 13C to urinary uric acid. A similar slow contribution of 13C to urinary uric acid was observed when AIC-1'C was administered (5) . The decline in abundance of '3C in urinary uric acid after adenine administration followed an exponential decline described by the formula dI/dt = K'I. Where I is isotope abundance, K' is a constant, and t is time. All subjects showed K' values in the same range except T. B., who showed a value almost twice that of either control subject or the other gout patients. This discordance in K' values as well as the fact that G. S. and T. B. each had a PRTase activity in the normal range provides evidence of metabolic heterogeneity among even those gout patients who have an excessive production of uric acid.
